MD Tox Laboratory

MD Tox Laboratory was paid $20.14M by Medicaid between Jan 2018 and Nov 2024, across 70 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 86% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	869	$471.15
2019	1,134	$177.82
2020	2,390	$136K
2021	145,012	$5.01M
2022	231,984	$11.85M
2023	64,209	$2.88M
2024incomplete	13,486	$265K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	86%	288,708	121,843	$17.41M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	9.6%	134,370	60,090	$1.93M
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.3%	6,607	4,233	$255K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.1%	2,276	981	$219K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	798	218	$56K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	1,578	1,195	$55K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	986	249	$33K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	756	748	$18K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	751	746	$18K
84443	Thyroid stimulating hormone (TSH)	<1%	2,220	2,185	$15K
80061	Lipid panel	<1%	2,528	2,488	$14K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	822	819	$14K

58 more codes

80053	Comprehensive metabolic panel	<1%	2,977	$13K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,362	$10K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,096	$9K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	210	$9K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	2,827	$9K
86480		<1%	213	$8K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	100	$7K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	215	$4K
86592		<1%	880	$3K
84439		<1%	471	$2K
81001		<1%	1,089	$1K
87086	Culture, bacterial; quantitative colony count, urine	<1%	482	$1K
86762		<1%	110	$1K
85027		<1%	387	$1K
87517		<1%	44	$1K
86780		<1%	111	$1K
87340		<1%	161	$1K
86803		<1%	116	$1K
84481		<1%	117	$902.43
84153		<1%	164	$890.17
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	62	$848.92
10005		<1%	25	$812.50
87511		<1%	46	$648.79
87481		<1%	29	$550.28
84144		<1%	26	$481.39
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	15	$439.77
80055		<1%	12	$425.64
82607		<1%	234	$424.98
82043		<1%	160	$385.78
84702		<1%	23	$357.53
82570		<1%	154	$320.41
86769		<1%	12	$294.91
82670		<1%	14	$279.18
82728		<1%	135	$271.62
86703		<1%	20	$238.00
86850		<1%	100	$232.82
83540		<1%	167	$231.82
86900		<1%	107	$227.92
86787		<1%	17	$191.70
82746		<1%	68	$183.11
86706		<1%	28	$171.80
84550		<1%	170	$151.60
88174		<1%	13	$145.60
36415	Collection of venous blood by venipuncture	<1%	464	$104.79
82627		<1%	12	$97.10
87184		<1%	112	$96.85
83550		<1%	14	$90.52
82274		<1%	12	$84.42
86901		<1%	26	$55.80
80048	Basic metabolic panel (calcium, ionized)	<1%	28	$49.00
85651		<1%	29	$44.87
83735		<1%	32	$41.66
82947		<1%	14	$38.60
82565		<1%	16	$38.43
80076		<1%	26	$27.25
83690		<1%	14	$18.06
85610		<1%	13	$17.65
83880		0%	103	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWHITE, DAVID (CEO)

Same official

Other billing entities under WHITE, DAVID

Full network →

Provider	Location	Paid
Coordinated Transportation Solutions, INC.	Trumbull, CT	$95.15M
Aems	Spring Creek, NV	$1.14M
Hot Springs School District	Hot Springs, AR	$583K
Aems	Elko, NV	$323K
Aspire Health Concepts, INC	Harrisburg, PA	$450.00

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.